Drug Trial Radar · NCT02163577
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
Last checked: Nov 20, 2026Latest source record: May 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Jul 2, 2014
Primary completion
Oct 30, 2018
Study completion Oct 30, 2018
Sponsor
- Lead sponsor
- Kyowa Kirin, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Kyowa Kirin Co., Ltd.
- First posted
- Jun 13, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of the study are to: * Identify a dose and dosing regimen of burosumab, based on safety and pharmacodynamic (PD) effect, in pediatric XLH participants * Establish the safety profile of burosumab for the treatment of children with XLH including ectopic mineralization risk, cardiovascular effects, and immunogenicity profile * Characterize the pharmacokinetic (PK)/PD profile of the KRN23 doses tested in the monthly (Q4) and biweekly (Q2) dose regimens in pediatric XLH patients * Determine the PD effects of burosumab treatment on markers of bone health in pediatric XLH patients * Obtain a preliminary assessment of the clinical effects of burosumab on bone health and deformity, muscle strength, and motor function * Obtain a preliminary assessment of the effects of burosumab on participant-reported outcomes, including pain, disability, and quality of life in pediatric XLH patients * Evaluate the long-term safety and efficacy of burosumab
Conditions
- X-linked Hypophosphatemia
Interventions
burosumabBiological
solution for SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in RSS Total Score Over TimeTime frame: Baseline, Week 40, 64, 160
- Change From Baseline in Serum Phosphorus Over TimeTime frame: Baseline, Week 40, 64, 160
- Change From Baseline in Serum 1,25(OH)2D Over TimeTime frame: Baseline, Week 40, 64, 160
- Change From Baseline in TmP/GFR Over TimeTime frame: Baseline, Week 40, 64, 160
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
Yale University School of Medicine
New Haven, Connecticut
Indiana University Hospital
Indianapolis, Indiana
Shriners Hospital for Children
St Louis, Missouri
Bicetre Hospital
Le Kremlin-Bicêtre, France
University Medical Center Groningen
Groningen, Netherlands
Birmingham Children's University
Birmingham, United Kingdom
Great Ormond Street Hospital
London, United Kingdom
Royal Manchester Hospital
Manchester, Lancashire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.